NYU
Precision Medicine Startup Ataraxis AI Nabs $20.4M in Series Financing
Ataraxis AI will use the new funding to bring to market its first offering, Ataraxis Breast, an AI-native prognostic/predictive platform for breast cancer.
Researchers explored whether the uptake of pre-test education and cancer risk genetic testing was similar for patients who used a chatbot or met with a genetic counselor.
Using Arima's technology, NYU researchers were able to identify a novel rearrangement in the PDL-1 gene in a pediatric brain tumor, which led to treatment with immunotherapy.
Micronoma, NYU Partner to Develop Microbial Biomarkers of Lung Cancer
Micronoma aims to commercialize the biomarkers as a test based on its OncobiotaLUNG microbiome-based liquid biopsy platform.
At AACR, the company highlighted new prospective and retrospective data that it believes helps set its platform apart from other available ctDNA technologies.